Bayou Vantage logo
AboutServicesResultsInsightsWork With Me

Regulatory Intelligence

Insights for Regulated Quality

Expert analysis on quality systems, inspection readiness, AI governance, and regulatory excellence. Updated weekly.

Sort by:

Filter by Category:

Popular Topics

Software Quality Assurance

A Mobile Device Is a System: Governing Connectivity, Registration and Backup at the Point of Care

On October 9, 2026, FDA published an early alert describing a software app or transducer connection problem on a portable ultrasound system. Per the alert, the app may not recognize a previously registered transducer, prompting re-registration without warning before point-of-care use, and scanning is blocked until registration completes. Registration requires Wi-Fi or cellular access. The manufacturer has reported pre-hospital events, outside network coverage, where those prompts prevented scanning and delayed care. As of September 29, 2026, the manufacturer reported eight serious injuries and four deaths associated with the issue. Nothing in that sequence is a hardware defect in the ordinary sense. The transducer works. The tablet works. The dependency that failed was a network connection nobody counted as part of the device.

5 min read10/10/2026
Medical Devices / Quality Systems / Supplier Governance

When Quality Controls Fail to Trigger: A Control-Chain Test

FDA issued a warning letter to Unilam Co., LTD on September 22, 2026, citing six quality system violations plus separate electronic product radiation control findings. Read as a list, it is six unrelated problems. Read as a system, it is one problem appearing six times: controls that exist on paper but do not fire when the condition they were built for actually occurs. A risk file that lists four items. A calibration range that excludes the wavelengths the product emits. A supplier change notification written as a request rather than an obligation. Each is defensible alone. Together they describe a chain where one break stops the sequence and nobody downstream finds out. This article sets out the five properties that make a control operational, works through what FDA reported in each domain, and gives you a one-material trace to test your own chain.

5 min read10/7/2026
Regulatory Strategy

The CMC Critical Path: What Accelerated Programs Must Make Visible

FDA began accepting year-five requests for its CMC Development and Readiness Pilot on October 1, 2026. It will select no more than nine proposals this fiscal year, and it has said it will stop accepting new applications at the end of April 2027 as PDUFA VII closes. This is the last window. The eligibility rules are not the story. What FDA asks sponsors to submit is. The required CMC Development Plan covers remaining tasks with timeframes, commercial manufacturing strategy, facility identification, product availability assurance, stability and validation plans, and anticipated challenges. That is a request for a critical path, not a status report. Most accelerated programs cannot produce one. Clinical timelines compress while CMC dependencies hold their original durations, and the gap stays invisible until it is too late to close. This article sets out the operating model, the governance that holds it, and a 30-day diagnostic.

5 min read10/5/2026
Medical Devices - Premarket Strategy

From System Description to Lifecycle Control: Building the Evidence Architecture for Complex Medical Devices

On September 25, 2026, FDA issued a draft guidance on premarket submissions for robotically-assisted surgical devices, open for comment until November 24. It is draft, nonbinding and not for implementation. It is also an unusually explicit map of how evidence has to interlock when a device combines mechanics, software, networks, reusable instruments and a team of users. The lesson generalizes past robotic surgery. Submission readiness is not a volume problem. Organizations rarely lack documents. What they lack is the ability to walk a reviewer from a labeling claim back to the system behavior that justifies it, without a gap. This article reads the draft as an architecture rather than a checklist, then sets out an executive evidence ledger and a 30-day diagnostic for testing whether those connections exist in your own quality system.

5 min read9/28/2026
GxP quality systems

The Record Is Part of the Barrier: Governing Aseptic Interventions as Operational Evidence

FDA's August 2026 warning letter to Jabil Inc. documented a batch record at Pharmaceutics International in Cockeysville, Maryland showing 12 aseptic interventions during filling when records indicated approximately 200 were conducted. Critical interventions, including removing vials from the filling zone, went undocumented. FDA placed the finding under quality unit oversight, not documentation alone. That gap is not administrative. The intervention record is a control input to sterility assurance. Without it, batch review cannot assess what it cannot see, contamination investigations cannot time-align microbial recoveries against line activity, process simulations are designed against a fictional intervention profile, and CAPA effectiveness collapses into training completion. This article sets out a governance model: a controlled intervention taxonomy, contemporaneous capture that does not itself add aseptic risk, reconciliation against independent evidence, Quality Unit decision rights, and effectiveness criteria that measure operational improvement rather than procedure revision.

5 min read9/28/2026
Data Integrity

Terminating the Employee Is Not the CAPA: A Systems Approach to Data Integrity

When a firm discovers data integrity misconduct, the fastest path to closure is to identify the individual, terminate, and close the record. FDA has now told a manufacturer, in writing, that this is not a corrective action. This article sets out a four-layer investigation framework covering individual conduct, failed controls, management environment, and Quality governance, along with ten questions for your Executive Quality Council.

5 min read8/6/2026
GxP quality systems

What your quality system is telling investigators before they ask a single question

A practical look at the documentation patterns, CAPA closure trends, and change control backlogs that experienced FDA investigators read on arrival — and what they signal about the underlying quality culture.

5 min read7/18/2026
Inspection readiness

If Inspection Readiness Starts With an Inspection Date, You Are Already Behind

The difference between organizations that sustain inspection readiness and those that sprint to it. Covers the specific operating model decisions — documentation governance, CAPA accountability, deviation trending, and readiness program continuity.

5 min read7/18/2026
Regulatory interpretation

Your Software Vendor Cannot Make You Part 11 Compliant

A vendor can provide software with Part 11 capabilities. It cannot determine intended use, validate your regulated process, govern access, review audit trails, or defend your controls during an FDA inspection.

5 min read7/18/2026

Stay Updated on Regulatory Excellence

Get weekly insights on quality systems, inspection readiness, and AI governance for regulated industries.

We respect your privacy. Unsubscribe at any time.